Found 5 clinical trials
COMMANDS - Myelodysplastic Syndromes (MDS) - ACE536-MDS-002 - Australia
) versus epoetin alfa for the treatment of anemia due to IPSS-R very low, low or intermediate risk MDS in ESA naïve subjects who require RBC transfusions. The study is divided into the Screening
- 16800 views
- 22 Aug, 2022
- 7 locations
COMMANDS - Myelodysplastic Syndromes (MDS) - ACE536-MDS-002 - US
luspatercept (ACE-536) versus epoetin alfa for the treatment of anemia due to IPSS-R very low, low or intermediate risk MDS in ESA naïve subjects who require RBC transfusions. The
- 54541 views
- 22 Aug, 2022
- 9 locations
COMMANDS - Myelodysplastic Syndromes (MDS) - ACE536-MDS-002 – Canada
safety of luspatercept (ACE-536) versus epoetin alfa for the treatment of anemia due to IPSS-R very low, low or intermediate risk MDS in ESA naïve subjects who require RBC transfusions.  
- 23120 views
- 22 Aug, 2022
- 10 locations
ErythroPOietin Alfa to Prevent Mortality and Reduce Severe Disability in Critically Ill TRAUMA Patients (EPO-TRAUMA)
The EPO-TRAUMA study is a prospective, multi-centre, double-blind, phase III, randomised controlled trial evaluating the efficacy of epoetin alfa compared to placebo in reducing mortality and
- 214 views
- 04 Oct, 2022
- 21 locations
A Trial Testing Early vs Late Onset of EPO Alfa Treatment in Lower Risk MDS
This is an open-label, randomized, multicenter, phase III study Patients with baseline Hb comprised between 9 and 10.5g/dl will be randomized to receive EPO Alfa 60000 UI/week for at least 12 weeks: Either at diagnosis Or at the Hb threshold chosen for RBC transfusions (must be < 9g/dl)
- 0 views
- 27 Jan, 2021
- 39 locations